Joel Ackerman, Chief Executive Officer commented, "Uplisting to a national exchange like NASDAQ has been a goal towards which we have been working for years. We are pleased to reach this important milestone in the Company's history. We expect this will provide us with increased visibility in the capital markets and access to a broader investor base, which ultimately should provide us with better access to capital."
Champions' common stock began trading under the same symbol (CSBR) at the opening of trading on August 21, 2015.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. Champions TumorGraft models are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.